MedWatch

Surge in counterfeit drug-incidents increases the need for EU-barcodes

A change is on the way in the European pharmaceutical industry. It is called coding and is going to help avert counterfeiting scandals, such as the recent Avastin controversy in the US. But it is going to be costly for the companies.

Foto: Lif/PR- Ulla Høegh

Worldwide reports of counterfeit drugs have increased more than ten-fold from 2002 to 2010. The surge also leads to an increase in the risk of counterfeit drugs infiltrating Europe’s legal distribution system.

“Counterfeiting is an increasing problem world-wide. In the chain of legal distribution there is a higher risk of counterfeiting. We have seen it in Europe, and the US is highly affected by it as well, and China probably to an even larger extent,” says Ulla Høegh, chief consultant for LIF – the Danish pharmaceutical industry union.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier